CN-121971470-A - Application of anoectoin in preparation of medicines for inhibiting metabolic inflammation and improving obesity

Abstract

The invention discloses an application of anoectoin in preparing a medicament for inhibiting metabolic inflammation and improving obesity, wherein the anoectoin can maintain tolerogenicity of anoectoin by regulating and controlling an immune system, inducing dendritic cells to express an immunosuppressive molecule PD-L1 and inhibiting a co-stimulatory molecule CD 86. This action in turn inhibits downstream T cell activation and infiltration, and eventually reduces recruitment and activation of macrophages in adipose and liver tissue, breaking the vicious circle of metabolic inflammation. Animal experiments show that the anoectochilus formosanus glycoside can effectively inhibit weight increase induced by high-fat diet and improve abnormal glucose tolerance, insulin resistance, liver lipid deposition and blood lipid disorder. The invention discloses the effect of anoectoin on treating obesity and related complications thereof through targeting an immune metabolism axis for the first time, and provides a new strategy and candidate compounds for developing novel and safe anti-obesity drugs.

Inventors

• LUO XIAOPING
• ZHANG CAI
• YANG XI
• HOU LING
• WANG HUANYU

Assignees

• 华中科技大学同济医学院附属同济医院

Dates

Publication Date

20260505

Application Date

20260327

Claims (9)

1. 1. Application of anoectoin in preparing medicine for preventing and/or treating obesity is provided.
2. 2. The use of anoectoin according to claim 1, in preparing a medicament for preventing and/or treating obesity, wherein the medicament is used for preventing and/or treating obesity or related complications caused by obesity, wherein the related complications comprise at least one of abnormal glucose metabolism caused by metabolic inflammation, insulin resistance, fatty liver and dyslipidemia.
3. 3. Use of anoectoin according to claim 1, in the manufacture of a medicament for preventing and/or treating obesity, wherein the anoectoin prevents and/or treats obesity by inhibiting metabolic inflammation.
4. 4. Use of anoectoin according to claim 3, in the preparation of a medicament for preventing and/or treating obesity, wherein the inhibiting metabolic inflammation comprises inducing immune tolerance of dendritic cells.
5. 5. The use of anoectoin according to claim 4, in preparing a medicament for preventing and/or treating obesity, wherein the inducing immune tolerance of dendritic cells comprises up-regulating expression of dendritic cell surface PD-L1 and/or down-regulating expression of dendritic cell surface CD 86.
6. 6. Use of anoectoin according to claim 3, in the preparation of a medicament for preventing and/or treating obesity, wherein the inhibiting metabolic inflammation comprises reducing infiltration of macrophages in adipose tissue and liver.
7. 7. Use of anoectoin according to claim 3, in the preparation of a medicament for preventing and/or treating obesity, wherein the inhibiting metabolic inflammation comprises reducing activation and infiltration of T cells in adipose tissue and liver.
8. 8. A pharmaceutical composition is characterized by comprising a therapeutically effective amount of anoectoin and a pharmaceutically acceptable carrier, wherein the purity of the anoectoin is more than or equal to 98 percent.
9. 9. The pharmaceutical composition of claim 8, wherein the pharmaceutical composition is administered by intraperitoneal injection.

Description

Application of anoectoin in preparation of medicines for inhibiting metabolic inflammation and improving obesity Technical Field The invention belongs to the technical field of biological medicines, and particularly relates to application of anoectoin in preparation of medicines for inhibiting metabolic inflammation and improving obesity. Background Obesity is a chronic low-grade inflammation and systemic metabolic disease characterized by excessive accumulation of multiple visceral fat and inflammatory infiltration in the body, often accompanied by complications such as type 2 diabetes, insulin resistance and cardiovascular disease, and causing a heavy burden on human health and economy. Metabolic inflammation is a key element of the pathogenesis of obesity and is also a key element in promoting obesity-related metabolic disorders and insulin resistance. The intake of excess nutrients can activate inflammatory reactions in different metabolic tissues, leading to infiltration of immune cells (such as macrophages, dendritic cells and T cells) and production of a large number of inflammatory factors, thereby causing ectopic deposition of lipids and metabolic dysfunction, exacerbating the progress of obesity. At present, clinically, drugs for treating obesity (such as orlistat, bupropion, liraglutide, phentermine and the like) mainly act by reducing fat absorption or appetite, but still have the problems of more side effects, poor patient tolerance, unsatisfactory effect and the like. The anoectochilus formosanus glycoside is a natural product extracted from the Chinese herbal medicine anoectochilus formosanus, and has the advantages of simple structure, good stability and the like. The existing research reports that anoectoin has the effects of immunosuppression and antioxidation stress, but no report on the application of anoectoin in inhibiting metabolic inflammation to prevent obesity and related complications exists so far. Therefore, the research and development of a drug for targeted treatment of metabolic inflammation has important clinical significance. Disclosure of Invention The invention aims to provide an application of anoectoin in preparing a medicament for inhibiting metabolic inflammation and improving obesity, and the invention can reduce infiltration and activation of macrophages by inhibiting inflammatory activation of dendritic cells and progress of activation proliferation and infiltration of induced T cells, so that the anoectoin can effectively inhibit inflammation, can block malignant circulation of inflammation, and can obtain good treatment effect in pharmacodynamics experiments of obesity disease models of abnormal lipid deposition and glycolipid metabolic disorder of liver and fat and other tissues. To achieve the above object, the present invention provides, in a first aspect, the use of anoectoin in the preparation of a medicament for preventing and/or treating obesity. In a first aspect, the medicament is for the prevention and/or treatment of obesity or related complications caused by obesity, including at least one of abnormal glucose metabolism caused by metabolic inflammation, insulin resistance, fatty liver and dyslipidemia. In a first aspect, the anoectoin prevents and/or treats obesity by inhibiting metabolic inflammation. In a first aspect, the inhibiting metabolic inflammation comprises inducing immune tolerance of dendritic cells. In a first aspect, the inducing immune tolerance of the dendritic cell comprises up-regulating expression of dendritic cell surface PD-L1 and/or down-regulating expression of dendritic cell surface CD 86. In a first aspect, the inhibiting metabolic inflammation comprises reducing infiltration of macrophages in adipose tissue and liver. In a first aspect, the inhibiting metabolic inflammation comprises reducing activation and infiltration of T cells in adipose tissue and liver. The invention provides a pharmaceutical composition, which comprises a therapeutically effective amount of anoectoin and a pharmaceutically acceptable carrier, and is used for preventing and/or treating obesity, wherein the purity of the anoectoin is more than or equal to 98%. In a second aspect, the pharmaceutical composition is administered by intraperitoneal injection. The invention has the beneficial effects that: (1) The invention provides the application of the natural product anoectoin in preparing the medicine for preventing and/or treating obesity and related complications thereof for the first time, and the anoectoin has the advantages of simple structure, good stability and no toxic or side effect, so as to provide a new potential safer choice for solving the problems of more side effects, poor tolerance and the like possibly existing in the existing anti-obesity medicines (such as orlistat, liraglutide and the like). (2) The invention proves the way of promoting the metabolic inflammation progress by the mutual crosstalk between the innate immune cells and t